星雲股份(300648.SZ):全資子公司擬增加註冊資本及變更名稱
格隆匯 2 月 5日丨星雲股份(300648.SZ)公佈,福州星雲軟件技術有限公司(“星雲軟件”)系公司下屬的主要從事軟件開發運行及自動化設備的研發、生產、調試、安裝以及技術服務的全資子公司,註冊資本為人民幣1000萬元,星雲股份認繳出資額為人民幣1000萬元,持股比例為100%。
為進一步增強星雲軟件的業務能力和資金實力,公司擬使用自有資金向其增加人民幣2000萬元的註冊資本,星雲軟件擬更名為福建星雲軟件技術有限公司(暫定名,最終以市場監督管理部門核准登記的名稱為準)。此次增資完成後,星雲軟件的註冊資本將由人民幣1000萬元增至人民幣3000萬元,公司仍持有100%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.